Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: a series from lysa centers C Rossi, J Gilhodes, M Maerevoet, C Herbaux, F Morschhauser, P Brice, ... American journal of hematology 93 (8), 1042-1049, 2018 | 99 | 2018 |
Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous … A de Masson, M Beylot-Barry, JD Bouaziz, RP de Latour, F Aubin, ... haematologica 99 (3), 527-534, 2014 | 83 | 2014 |
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in … X Leleu, G Fouquet, B Hebraud, M Roussel, D Caillot, ML Chrétien, ... Leukemia 27 (11), 2242-2244, 2013 | 76 | 2013 |
Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma S Garciaz, D Coso, F Peyrade, S Fürst, S Duran, B Chetaille, ... Hematological oncology 32 (4), 187-191, 2014 | 68 | 2014 |
Bendamustine‐based conditioning prior to autologous stem cell transplantation (ASCT): results of a French multicenter study of 474 patients from LYmphoma Study Association … SP Chantepie, S Garciaz, E Tchernonog, F Peyrade, MV Larcher, M Diouf, ... American journal of hematology 93 (6), 729-735, 2018 | 46 | 2018 |
Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity S Garciaz, D Coso, JM Schiano de Collela, F Broussais, AM Stoppa, ... Bone Marrow Transplantation 51 (2), 319-321, 2016 | 44 | 2016 |
Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients S Garciaz, MA Hospital, AS Alary, C Saillard, Y Hicheri, B Mohty, J Rey, ... Cancers 14 (8), 2025, 2022 | 37 | 2022 |
Regulation of the positive transcriptional effect of PLZF through a non-canonical EZH2 activity M Koubi, M Poplineau, J Vernerey, L N’Guyen, G Tiberi, S Garciaz, ... Nucleic acids research 46 (7), 3339-3350, 2018 | 30 | 2018 |
Contiguous follicular lymphoma and follicular lymphoma in situ harboring N-glycosylated sites E Mamessier, C Drevet, F Broussais-Guillaumot, ML Mollichella, ... Haematologica 100 (4), e155, 2015 | 27 | 2015 |
Pharmacologic reduction of mitochondrial iron triggers a noncanonical BAX/BAK-dependent cell death S Garciaz, AA Guirguis, S Müller, FC Brown, YC Chan, A Motazedian, ... Cancer Discovery 12 (3), 774-791, 2022 | 26 | 2022 |
Patients’ non-medical characteristics contribute to collective medical decision-making at multidisciplinary oncological team meetings L Restivo, T Apostolidis, AD Bouhnik, S Garciaz, T Aurran, ... PLoS One 11 (5), e0154969, 2016 | 24 | 2016 |
Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a … T Hueso, T Gastinne, S Garciaz, E Tchernonog, C Delette, ... Bone marrow transplantation 55 (6), 1076-1084, 2020 | 23 | 2020 |
Lenalidomide for the treatment of B-cell lymphoma S Garciaz, D Coso, JM Schiano de Colella, R Bouabdallah Expert Opinion on Investigational Drugs 25 (9), 1103-1116, 2016 | 23 | 2016 |
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights JE Martin, S Khalife-Hachem, T Grinda, M Kfoury, S Garciaz, F Pasquier, ... Annals of Oncology 32 (8), 1046-1048, 2021 | 22 | 2021 |
Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available S Garciaz, L Castagna, R Bouabdallah, S Fürst, S Bramanti, D Coso, ... Bone marrow transplantation 50 (6), 865-867, 2015 | 22 | 2015 |
A first-in-human phase 1 study of the menin-KMT2A (MLL1) inhibitor JNJ-75276617 in adult patients with relapsed/refractory acute leukemia harboring KMT2A or NPM1 alterations E Jabbour, E Searle, M Abdul-Hay, S Abedin, I Aldoss, AA Piérola, ... Blood 142, 57, 2023 | 21 | 2023 |
Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses KL Chan, J Gomez, C Cardinez, N Kumari, CE Sparbier, EYN Lam, ... Cancer Cell 40 (10), 1190-1206. e9, 2022 | 17 | 2022 |
Venetoclax in acute myeloid leukemia: molecular basis, evidences for preclinical and clinical efficacy and strategies to target resistance S Garciaz, C Saillard, Y Hicheri, MA Hospital, N Vey Cancers 13 (22), 5608, 2021 | 15 | 2021 |
Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a … S Garciaz, M Loschi, A De Masson, L Biard, M Mercier, C Tomowiak, ... Leukemia & Lymphoma, 2019 | 15 | 2019 |
Therapy-related myeloid neoplasms following PARP inhibitors: real-life experience V Marmouset, J Decroocq, S Garciaz, G Etienne, A Belhabri, S Bertoli, ... Clinical Cancer Research 28 (23), 5211-5220, 2022 | 14 | 2022 |